Exact Mass: 311.13035560000003
Exact Mass Matches: 311.13035560000003
Found 143 metabolites which its exact mass value is equals to given mass value 311.13035560000003,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
IMAZAQUIN
C17H17N3O3 (311.12698520000004)
D010575 - Pesticides > D006540 - Herbicides D016573 - Agrochemicals CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7950; ORIGINAL_PRECURSOR_SCAN_NO 7948 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7948; ORIGINAL_PRECURSOR_SCAN_NO 7947 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3770; ORIGINAL_PRECURSOR_SCAN_NO 3769 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3779; ORIGINAL_PRECURSOR_SCAN_NO 3778 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3762; ORIGINAL_PRECURSOR_SCAN_NO 3761 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7947; ORIGINAL_PRECURSOR_SCAN_NO 7945 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3761; ORIGINAL_PRECURSOR_SCAN_NO 3760 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7928; ORIGINAL_PRECURSOR_SCAN_NO 7927 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7919; ORIGINAL_PRECURSOR_SCAN_NO 7918 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7962; ORIGINAL_PRECURSOR_SCAN_NO 7957 CONFIDENCE standard compound; INTERNAL_ID 1252; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3745; ORIGINAL_PRECURSOR_SCAN_NO 3744 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3711
Domoic acid
C15H21NO6 (311.13688060000004)
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents Isodomoic acid F is found in mollusks. Isodomoic acid F is isolated from mussels. Isolated from mussels. Isodomoic acid F is found in mollusks.
Isodomoic acid A
C15H21NO6 (311.13688060000004)
An L-proline derivative that is L-proline substituted by a carboxymethyl group at position 3 and a 6-carboxyhepta-2,5-dien-2-yl group at position 4. It is isolated from the red alga, Chondria armata. D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins
Tolazamide
C14H21N3O3S (311.13035560000003)
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent D007004 - Hypoglycemic Agents CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4274; ORIGINAL_PRECURSOR_SCAN_NO 4272 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4225; ORIGINAL_PRECURSOR_SCAN_NO 4223 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4245; ORIGINAL_PRECURSOR_SCAN_NO 4243 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4316; ORIGINAL_PRECURSOR_SCAN_NO 4314 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4224; ORIGINAL_PRECURSOR_SCAN_NO 4220 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8447; ORIGINAL_PRECURSOR_SCAN_NO 8445 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8470; ORIGINAL_PRECURSOR_SCAN_NO 8469 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8494; ORIGINAL_PRECURSOR_SCAN_NO 8491 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8497; ORIGINAL_PRECURSOR_SCAN_NO 8496 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8468; ORIGINAL_PRECURSOR_SCAN_NO 8463 CONFIDENCE standard compound; INTERNAL_ID 272; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8506; ORIGINAL_PRECURSOR_SCAN_NO 8504
N2N2-Dimethylguanosine
CONFIDENCE standard compound; INTERNAL_ID 311 N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA. N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA.
N2,N2-Dimethylguanosine
N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA. The mean levels of urinary N2,N2-Dimethylguanosine in the patients with colorectal cancer are significantly higher than those in patients with intestinal villous adenoma or the healthy adults (PMID 15991285). N2,N2-Dimethylguanosine has been identified in the human placenta (PMID: 32033212). N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA. N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA. N2,N2-Dimethylguanosine is an urinary nucleoside, a primary degradation product of tRNA.
1,7-Dimethylguanosine
1,7-dimethylguanosine is a modified ribonucleoside. 1,7-dimethylguanosine is formed in tRNA enzymatic methylation. 1,7-Dimethylguanosine was found to be formed in high amounts in the tRNA methylation reaction at high concentrations of methylating agents.1,7-dimethylguanosine has a possible connection to chemical cancerogenesis and to the aberrant increase of tRNA methylases activity in tumor tissues. The amount of 1,7-dimethylguanosine produced by the kidney is higher than that produced by the liver. The immediate precursor in the formation of 1,7-dimethylguanosine in tRNA appears to be 1-methylguanosine. An accumulation of modified ribonucleosides appears in the serum of uremic patients. (PMID: 7046770, 6164398, 7259877, 7159514, 9607216) [HMDB] 1,7-dimethylguanosine is a modified ribonucleoside. 1,7-dimethylguanosine is formed in tRNA enzymatic methylation. 1,7-Dimethylguanosine was found to be formed in high amounts in the tRNA methylation reaction at high concentrations of methylating agents.1,7-dimethylguanosine has a possible connection to chemical cancerogenesis and to the aberrant increase of tRNA methylases activity in tumor tissues. The amount of 1,7-dimethylguanosine produced by the kidney is higher than that produced by the liver. The immediate precursor in the formation of 1,7-dimethylguanosine in tRNA appears to be 1-methylguanosine. An accumulation of modified ribonucleosides appears in the serum of uremic patients. (PMID: 7046770, 6164398, 7259877, 7159514, 9607216).
Tolazamide
C14H21N3O3S (311.13035560000003)
Tolazamide is only found in individuals that have used or taken this drug. It is a sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. [PubChem]Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent D007004 - Hypoglycemic Agents
5-(N,N-Hexamethylene)amiloride
D000970 - Antineoplastic Agents
1-(4-Aminophenyl)-7,8-dimethoxy-3,5-dihydro-2,3-benzodiazepin-4-one
C17H17N3O3 (311.12698520000004)
CFM-2 is a potent and selective non-competitive AMPAR antagonist[1]. CFM-2 possesses anticonvulsant activity in various models of seizures[2].
Dothiepin sulfoxide
C19H21NOS (311.13437760000005)
(2S,3S,4S)-4-[(6S)-6-Carboxyhepta-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
Dehydro-isolongistrobin|Dehydroisolongistrobin
C17H17N3O3 (311.12698520000004)
methyl 1-((2-methyl carbamate)ethyl)-beta-carboline-3-carboxylate
C17H17N3O3 (311.12698520000004)
Domoic acid
C15H21NO6 (311.13688060000004)
An L-proline derivative that is L-proline substituted by a carboxymethyl group at position 3 and a 6-carboxyhepta-2,4-dien-2-yl group at position 4. It is produced by the diatomic algal Pseudo-nitzschia. It is an analogue of kainic acid and a neurotoxin which causes amnesic shellfish poisoning (ASP). D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents
1-Propanamine, N,N-dimethyl-3-(5-oxidodibenzo[b,e]thiepin-11(6H)-ylidene)-, (E)- (9CI)
C19H21NOS (311.13437760000005)
(S)-(+)-N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
C19H21NOS (311.13437760000005)
1-(3,4-Methylenedioxyphenyl)-2-pyrrolidino-1-pentanone hydrochloride
C16H22ClNO3 (311.12881319999997)
5-Pyrimidinecarbonitrile, 4-amino-2-(2,5-dihydroxyphenyl)-6-(3-piperidinyl)-
tert-butyl 4-[(6-chloropyridin-3-yl)methyl]piperazine-1-carboxylate
N-[(2R,3S)-2-(2,5-difluorophenyl)-3,4-dihydro-2H-pyran-3-yl]-Carbamic acid 1,1-dimethylethyl ester
C16H19F2NO3 (311.13329280000005)
2-(N,N-Dimethylsulfamoyl)phenylboronic acid. pinacol ester
C14H22BNO4S (311.13625220000006)
3-(N,N-Dimethylsulfamoyl)phenylboronic acid, pinacol ester
C14H22BNO4S (311.13625220000006)
N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
C14H22BNO4S (311.13625220000006)
N-methyl-N-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanesulfonamide
C14H22BNO4S (311.13625220000006)
N-(4-METHOXYPHENYL)-2-(3-OXO-1,2,3,4-TETRAHYDROQUINOXALIN-2-YL)ACETAMIDE
C17H17N3O3 (311.12698520000004)
butyl prop-2-enoate,2-methylidenebutanedioic acid,prop-2-enenitrile
C15H21NO6 (311.13688060000004)
Benzyl 2-acetamido-2-deoxy-alpha-D-glucopyranoside
C15H21NO6 (311.13688060000004)
2-METHYLPHENYL 2-ACETAMIDO-2-DEOXY-β-D-GLUCOPYRANOSIDE
C15H21NO6 (311.13688060000004)
3-Piperidinecarboxylicacid, 4-oxo-1-(2-phenylethyl)-, ethyl ester, hydrochloride (1:1)
C16H22ClNO3 (311.12881319999997)
3-(4-chloro-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester
C16H22ClNO3 (311.12881319999997)
N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide
C14H22BNO4S (311.13625220000006)
2-benzyl-8-oxa-2-azaspiro[4.5]decane-4-carboxylic acid,hydrochloride
C16H22ClNO3 (311.12881319999997)
tert-butyl 4-(2-chlorophenoxy)piperidine-1-carboxylate
C16H22ClNO3 (311.12881319999997)
S-(+)-N,N-DIMETHYL-3-(1-NAPHTHLENYLOXY)-3-(2-THIENYL)-PROPANAMINE
C19H21NOS (311.13437760000005)
(4-(1-(((Benzyloxy)carbonyl)amino)cyclopropyl)phenyl)boronic acid
1-ISOPENTYL-7-PHENYL-1H-PYRIMIDO[4,5-D][1,3]OXAZINE-2,4-DIONE
C17H17N3O3 (311.12698520000004)
2H-1-Benzopyran-2-one,3-[2-(diethylamino)ethyl]-7-hydroxy-4-methyl-, hydrochloride (1:1)
C16H22ClNO3 (311.12881319999997)
1-N-BOC-4-(3-CHLOROPHENYL)-4-HYDROXYPIPERIDINE
C16H22ClNO3 (311.12881319999997)
(S)-N,N-dimethyl-3-(naphthalen-1-yloxy)-3-(thiophen-3-yl)propan-1-amine
C19H21NOS (311.13437760000005)
metahexamide
C14H21N3O3S (311.13035560000003)
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent
N,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
C14H22BNO4S (311.13625220000006)
Benzyl 2-Acetamido-2-deoxy-β-D-glucopyranoside
C15H21NO6 (311.13688060000004)
4-BOC-2-(4-CHLOROPHENYL)-2-METHYLMORPHOLINE
C16H22ClNO3 (311.12881319999997)
N6-(2-Hydroxyethyl)adenosine
N6-(2-Hydroxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
4-[5-(3,4-Diethoxyphenyl)-1,2,4-oxadiazol-3-yl]pyridine
C17H17N3O3 (311.12698520000004)
N-{2-[(4-Cyano-1,1-biphenyl-4-YL)oxy]ethyl}-N-hydroxy-N-methylurea
C17H17N3O3 (311.12698520000004)
(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
C15H21NO6 (311.13688060000004)
N2,N2-Dimethylguanosine (incomplete stereochemisrty)
N-(7-carboxy-7-demethylgeranyl)-L-glutamate
C15H21NO6-2 (311.13688060000004)
(3R,4R,5R,6R)-3-amino-6-[2-hydroxy-2-[(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]ethyl]oxane-2,4,5-triol
(3Z)-N,N-dimethyl-3-(5-oxo-6H-benzo[c][1]benzothiepin-11-ylidene)propan-1-amine
C19H21NOS (311.13437760000005)
(2S,3S,4S)-4-[(6S)-6-Carboxyhepta-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
3-(2,3-dihydro-1H-benzo[f]cyclopenta[c]quinolin-4-yl)phenol
5-(2-Ethoxyphenyl)-3-(2-methoxy-6-methyl-3-pyridinyl)-1,2,4-oxadiazole
C17H17N3O3 (311.12698520000004)
(2-Nitro-benzylidene)-(4-pyridin-2-yl-piperazin-1-yl)-amine
3-Chloro-1-cyclohexyl-4-(4-methyl-1-piperazinyl)pyrrole-2,5-dione
2-[[(4-Methyl-2-thiazolyl)amino]-oxomethyl]-1-pyrrolidinecarboxylic acid 2-methylpropyl ester
C14H21N3O3S (311.13035560000003)
1-(4-Methoxyphenyl)-1-methyl-3-(1-methyl-5-benzotriazolyl)urea
N-succinimidyl 5-(3-azidopropylamino)-5-oxopentanoate
CFM 2
C17H17N3O3 (311.12698520000004)
CFM-2 is a potent and selective non-competitive AMPAR antagonist[1]. CFM-2 possesses anticonvulsant activity in various models of seizures[2].
N(2),N(2)-Dimethylguanosine
A guanosine where the hydrogens of the amine group at C-2 are substituted by methyl groups.
2′-O-Methyl-8-methyl guanosine
2′-O-Methyl-8-methyl guanosine (m8Gm) is a Z-form RNA stabilizer. 2′-O-Methyl-8-methyl guanosine can markedly stabilize the Z-RNA at low salt conditions[1]. m8Gm-contained oligonucleotides stabilize the Z-DNA under low salt conditions[2].
(2s,3s,4s)-4-[(2e,4z,6r)-6-carboxy-6-methylhexa-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
(3r,4r,5s,6s,10z)-4,6-dihydroxy-2,3-dimethoxy-3-methyl-10-propylidene-2-azaspiro[4.5]dec-8-ene-1,7-dione
C15H21NO6 (311.13688060000004)
4,6-dihydroxy-4-{[5-(3-hydroxy-2-methylpropyl)-5-methyl-4-oxofuran-2-yl]methyl}-3,5-dihydropyridin-2-one
C15H21NO6 (311.13688060000004)
4,6-dihydroxy-4-{[(5r)-5-[(2s)-3-hydroxy-2-methylpropyl]-5-methyl-4-oxofuran-2-yl]methyl}-3,5-dihydropyridin-2-one
C15H21NO6 (311.13688060000004)
4-{[2-(2,4-dimethoxyphenyl)-1,2,4-triazol-3-yl]methyl}phenol
C17H17N3O3 (311.12698520000004)
4-(6-carboxy-6-methylhexa-2,5-dien-2-yl)-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
2-hydroxy-3,6-dimethyl-n-[(3r,4r,5r)-4,5,6-trihydroxy-4-methyloxan-3-yl]benzenecarboximidic acid
C15H21NO6 (311.13688060000004)
(2s,3s,4s)-4-[(5e)-6-carboxy-6-methylhexa-1,5-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
(2s,3s,4e)-4-[(3e,6r)-6-carboxy-6-methylhex-3-en-2-ylidene]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
3-({bis[(2-oxooxolan-3-yl)methyl]amino}methyl)oxolan-2-one
C15H21NO6 (311.13688060000004)
(2s,3s,4s)-4-[(2e,5e)-6-carboxy-6-methylhexa-2,5-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
2-hydroxy-3,6-dimethyl-n-(4,5,6-trihydroxy-4-methyloxan-3-yl)benzenecarboximidic acid
C15H21NO6 (311.13688060000004)
4-{[5-(2,3-dihydroxy-2-methylpropyl)-5-methyl-4-oxofuran-2-yl]methyl}-6-hydroxy-4,5-dihydro-3h-pyridin-2-one
C15H21NO6 (311.13688060000004)
(2r,3r,4s,5r)-2-{6-[(2-hydroxyethyl)amino]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol
(6s)-2-hydroxy-6-[2-(3-methylimidazol-4-yl)-2-oxoethyl]-4,6-dihydro-3h-1-benzazocin-5-one
C17H17N3O3 (311.12698520000004)
2-hydroxy-6-[2-(3-methylimidazol-4-yl)-2-oxoethyl]-4,6-dihydro-3h-1-benzazocin-5-one
C17H17N3O3 (311.12698520000004)
3-[3-(methoxycarbonyl)-9h-pyrido[3,4-b]indol-1-yl]-n-methylpropanimidic acid
C17H17N3O3 (311.12698520000004)
(3r,4r,5s,6r,10z)-4,6-dihydroxy-2,3-dimethoxy-3-methyl-10-propylidene-2-azaspiro[4.5]dec-8-ene-1,7-dione
C15H21NO6 (311.13688060000004)
4-{[(5r)-5-[(2r)-2,3-dihydroxy-2-methylpropyl]-5-methyl-4-oxofuran-2-yl]methyl}-6-hydroxy-4,5-dihydro-3h-pyridin-2-one
C15H21NO6 (311.13688060000004)
4-(6-carboxy-6-methylhexa-1,5-dien-2-yl)-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
4,6-dihydroxy-2,3-dimethoxy-3-methyl-10-propylidene-2-azaspiro[4.5]dec-8-ene-1,7-dione
C15H21NO6 (311.13688060000004)
(3r)-3-{[bis({[(3r)-2-oxooxolan-3-yl]methyl})amino]methyl}oxolan-2-one
C15H21NO6 (311.13688060000004)
2-[2-(dimethylamino)-6-hydroxypurin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
(2s,3s,4s)-4-[(2z,5e)-6-carboxy-6-methylhexa-2,5-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)
(2s,3s,4s)-4-[(2z,4z,6r)-6-carboxy-6-methylhexa-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
C15H21NO6 (311.13688060000004)